IMV Inc. said a combination of its lead drug candidate with Incyte Corp.'s investigational treatment epacadostat and chemotherapy was well-tolerated in advanced ovarian cancer patients whose disease returned after prior treatment.
The company was presenting data from an ongoing phase 1b/2 trial of DPX-Survivac at the 2018 American Society for Clinical Oncology.
The combination showed anti-cancer activity in seven of 18 evaluable patients, including four whose tumor size decreased by more than 30%. Study participants generally tolerated the treatment well with no related significant adverse events reported.
The study also evaluated blood samples and tumor biopsies of 10 evaluable patients. Results showed an increase in T cell infiltration, a type of white blood cell responsible for a variety of immune responses, in three study participants.
Of the three patients, two with T cell infiltration saw their tumors shrink significantly for more than a year. The third patient showed resistance to the treatment and saw the disease worsen.
The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.
